These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29978334)

  • 1. Anti-ADAM17 monoclonal antibody MEDI3622 increases IFNγ production by human NK cells in the presence of antibody-bound tumor cells.
    Mishra HK; Pore N; Michelotti EF; Walcheck B
    Cancer Immunol Immunother; 2018 Sep; 67(9):1407-1416. PubMed ID: 29978334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.
    Wu J; Mishra HK; Walcheck B
    J Leukoc Biol; 2019 Jun; 105(6):1297-1303. PubMed ID: 30786043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells.
    Matson AW; Hullsiek R; Dixon KJ; Wang S; Lindstedt AJ; Friess RR; Phung SK; Freedman TS; Felices M; Truckenbrod EN; Wu J; Miller JS; Walcheck B
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39053944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation.
    Lajoie L; Congy-Jolivet N; Bolzec A; Gouilleux-Gruart V; Sicard E; Sung HC; Peiretti F; Moreau T; Vié H; Clémenceau B; Thibault G
    J Immunol; 2014 Jan; 192(2):741-51. PubMed ID: 24337742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of an ADAM17 cleavage region in human CD16 (FcγRIII) and the engineering of a non-cleavable version of the receptor in NK cells.
    Jing Y; Ni Z; Wu J; Higgins L; Markowski TW; Kaufman DS; Walcheck B
    PLoS One; 2015; 10(3):e0121788. PubMed ID: 25816339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells.
    Pahl JHW; Koch J; Götz JJ; Arnold A; Reusch U; Gantke T; Rajkovic E; Treder M; Cerwenka A
    Cancer Immunol Res; 2018 May; 6(5):517-527. PubMed ID: 29514797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
    Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
    Front Immunol; 2022; 13():841859. PubMed ID: 35281028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cells.
    Matson AW; Hullsiek RH; Dixon KJ; Wang S; Lindstedt AJ; Friess RR; Phung SK; Freedman TS; Felices M; Truckenbrod EN; Wu J; Miller JS; Walcheck B
    bioRxiv; 2024 May; ():. PubMed ID: 38798522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of non-genetically modified, CAR-like, NK cells.
    Coënon L; Rigal E; Courot H; Multrier C; Zemiti S; Lambour J; Pugnière M; de Toledo M; Bossis G; Cartron G; Robert B; Martineau P; Fauvel B; Presumey J; Villalba M
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39029925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel anti-CD16a antibody clones for the development of effective natural killer cell engagers.
    Liao B; Tumanut C; Li L; Corper A; Challa D; Chang A; Begum H; Farokhi E; Woods C; Fan X
    MAbs; 2024; 16(1):2381261. PubMed ID: 39048914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
    van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
    Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.
    Zhu H; Blum RH; Bjordahl R; Gaidarova S; Rogers P; Lee TT; Abujarour R; Bonello GB; Wu J; Tsai PF; Miller JS; Walcheck B; Valamehr B; Kaufman DS
    Blood; 2020 Feb; 135(6):399-410. PubMed ID: 31856277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ectodomain shedding by ADAM17 (a disintegrin and metalloproteinase 17) in canine neutrophils.
    Snyder KM; McAloney CA; Montel JS; Modiano JF; Walcheck B
    Vet Immunol Immunopathol; 2021 Jan; 231():110162. PubMed ID: 33264689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Restricted processing of CD16a/Fc γ receptor IIIa
    Patel KR; Roberts JT; Subedi GP; Barb AW
    J Biol Chem; 2018 Mar; 293(10):3477-3489. PubMed ID: 29330305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma.
    Dixon KJ; Snyder KM; Khaw M; Hullsiek R; Davis ZB; Matson AW; Shirinbak S; Hancock B; Bjordahl R; Hosking M; Miller JS; Valamehr B; Wu J; Walcheck B
    Front Immunol; 2024; 15():1407567. PubMed ID: 39100677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy.
    Nikkhoi SK; Li G; Eleya S; Yang G; Vandavasi VG; Hatefi A
    Front Immunol; 2022; 13():1039969. PubMed ID: 36685519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc γ receptor IIIa/CD16a processing correlates with the expression of glycan-related genes in human natural killer cells.
    Patel KR; Rodriguez Benavente MC; Lorenz WW; Mace EM; Barb AW
    J Biol Chem; 2021; 296():100183. PubMed ID: 33310702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.